Navigation Links
Pearl Therapeutics Reports Positive Phase 2b Results of PT001 in Patients With COPD
Date:12/7/2011

muscarinic antagonist (LAMA) and a long-acting beta-2 agonist (LABA) delivered via a metered dose inhaler (HFA MDI); and PT010, a triple-combination product that combines the LAMA and LABA components of PT003 with an inhaled corticosteroid (ICS) for twice-daily administration from an HFA MDI for the treatment of severe COPD. Both PT003 and PT010 are developed with Pearl's proprietary porous particle cosuspension technology, which allows the formulation of multiple products in the MDI format, with highly stable, robust and aerodynamically efficient drug delivery. Founded in 2006, Pearl Therapeutics is privately held and backed by 5AM Ventures, Clarus Ventures, New Leaf Ventures and Vatera Healthcare. For more information, please visit www.pearltherapeutics.com.

(1) FEV1 (forced expiratory volumes in one second) is a common measurement of lung function in patients with asthma, cystic fibrosis, and COPD and is typically used to predict the severity of pulmonary disease. AUC (area under the curve) is a measure of therapeutic benefit over a period of time.

(2) Previously, Pearl has reported a comparative assessment of PT001 relative to Spiriva®, a long-acting, once-a-day, muscarinic antagonist.  See announcements dated May 18, 2010 and January 6, 2010 for more information.

Editor's note: Atrovent® HFA (Ipratropium Bromide) and Spiriva® HandiHaler® (tiotropium bromide inhalation powder) are registered trademarks of Boehringer Ingelheim Pharmaceuticals.


'/>"/>
SOURCE Pearl Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pearl Therapeutics Presents New Scientific Evidence Supporting Versatility of Its Novel Cosuspension MDI Platform
2. Anthera Announces Last Patient Enrolled in PEARL-SC Study
3. Pearl Therapeutics Bronchodilator Combination PT003 Provides Superior Inspiratory Capacity Compared to Spiriva®
4. Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
5. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
6. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
7. Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump
8. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
9. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
10. Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump
11. Echo Therapeutics to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... (NASDAQ: STAA ), a leading developer, manufacturer and marketer ... reported financial results for the second quarter ended July 3, ... Sales of $18.7 Million Down 7% from the Prior Year ... the Weakening Euro and Yen , ICL Units Increased ... Sales Down 1% Including Korea - Up 16% Excluding Korea ...
(Date:7/29/2015)... July 29, 2015 Neurocrine Biosciences, Inc. (NASDAQ: NBIX ... 30, 2015. For the second quarter of 2015, the Company reported ... compared to a net loss of $13.4 million, or $0.18 loss ... months ended June 30, 2015, the Company reported a net loss ... net loss of $25.2 million, or $0.35 loss per share, for ...
(Date:7/29/2015)... , July 29, 2015 Immune Pharmaceuticals Inc. ... secured financings of up to $21.5 million through two ... Inc. (NYSE: HTGC ) ("Hercules"), for a term loan ... mutual fund Discover Growth Fund ("Discover"), for the sale ... Preferred Stock ("Preferred Stock") for up to $12 million ...
Breaking Medicine Technology:STAAR Surgical Reports Second Quarter 2015 Results 2STAAR Surgical Reports Second Quarter 2015 Results 3STAAR Surgical Reports Second Quarter 2015 Results 4STAAR Surgical Reports Second Quarter 2015 Results 5STAAR Surgical Reports Second Quarter 2015 Results 6STAAR Surgical Reports Second Quarter 2015 Results 7STAAR Surgical Reports Second Quarter 2015 Results 8STAAR Surgical Reports Second Quarter 2015 Results 9STAAR Surgical Reports Second Quarter 2015 Results 10STAAR Surgical Reports Second Quarter 2015 Results 11STAAR Surgical Reports Second Quarter 2015 Results 12STAAR Surgical Reports Second Quarter 2015 Results 13STAAR Surgical Reports Second Quarter 2015 Results 14STAAR Surgical Reports Second Quarter 2015 Results 15STAAR Surgical Reports Second Quarter 2015 Results 16STAAR Surgical Reports Second Quarter 2015 Results 17STAAR Surgical Reports Second Quarter 2015 Results 18STAAR Surgical Reports Second Quarter 2015 Results 19STAAR Surgical Reports Second Quarter 2015 Results 20STAAR Surgical Reports Second Quarter 2015 Results 21STAAR Surgical Reports Second Quarter 2015 Results 22STAAR Surgical Reports Second Quarter 2015 Results 23STAAR Surgical Reports Second Quarter 2015 Results 24Neurocrine Biosciences Reports Second Quarter 2015 Results 2Neurocrine Biosciences Reports Second Quarter 2015 Results 3Neurocrine Biosciences Reports Second Quarter 2015 Results 4Neurocrine Biosciences Reports Second Quarter 2015 Results 5Neurocrine Biosciences Reports Second Quarter 2015 Results 6Neurocrine Biosciences Reports Second Quarter 2015 Results 7Neurocrine Biosciences Reports Second Quarter 2015 Results 8Neurocrine Biosciences Reports Second Quarter 2015 Results 9Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 2Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 3Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 4Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 5
(Date:7/29/2015)... ... July 29, 2015 , ... ... that Columbia University Medical Center, located in New York, NY, selected the ReadyCam ... easy for physicians and scientists to immediately access worldwide TV and cable news ...
(Date:7/29/2015)... NJ (PRWEB) , ... July 29, 2015 , ... Andrzej ... Dr. Andrzej Klos, a board-certified pediatrician for nearly 38 years, is motivated each and ... dedication and commitment to his profession shine alongside his many awards and accolades, which ...
(Date:7/29/2015)... ... ... " Core Organizer ” was featured on NewsWatch as part of its monthly AppWatch, ... iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted ... organized. , Wouldn’t it be great if everyone could be a little more organized? ...
(Date:7/29/2015)... ... July 29, 2015 , ... The report “Atherosclerosis - Pipeline ... is a slow, progressive disease that may start in childhood. The report strengthens ... products. Complete report on Atherosclerosis Pipeline with 78 market data tables and 15 ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... with its Topricin® Pain Relief and Healing Cream designated as the nonprofit’s natural ... that is actively addressing Line of Duty Deaths (LODD) and the high rate ...
Breaking Medicine News(10 mins):Health News:Columbia University Medical Center Installs a VideoLink ReadyCam® Video Studio on Campus; Medical Experts Able to Appear on Live TV at a Moment's Notice 2Health News:Columbia University Medical Center Installs a VideoLink ReadyCam® Video Studio on Campus; Medical Experts Able to Appear on Live TV at a Moment's Notice 3Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 2Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 3Health News:Get More Organized with the Core Organizer App 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 3Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 4Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 5Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 6
... that people choosing to live near to outdoor recreation amenities ... to an increase in all that healthy outdoor activity right ... looking at the relationship between reasons for choosing a neighbourhood ... not the case. In fact researchers found that ...
... 2010: Workplace wellness programmes play a vital role in ... Day(1) theme is to encourage employers and employees to ... The European Society of Cardiology(2) is keen to support ... two major initiatives at the next EuroPRevent Meeting(3) in ...
... month that MALAT1, a long non-coding RNA that is implicated ... in the earliest stage of protein production. Their study appears ... percent of the human genome codes for proteins, and scientists ... of the "non-coding" genome. Among the least studied non-coding genes ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, Sept. ... become narrowed, restricting blood flow to the brain, having a ... over a 10-year period, British researchers report. The carotid ... supplies blood carrying oxygen to the head, so a procedure ...
... victims of motorcycle crashes were 1.5 times more likely ... even though many more of the African-American victims were ... a new study by Johns Hopkins researchers. Results ... the August issue of the American Journal of ...
... UCLA,s Jonsson Comprehensive Cancer Center have discovered a new ... a pathway that, when defective, helps promote the formation ... and leukemia. , The new pathway, part of a ... some that have are known to cause cancer because, ...
Cached Medicine News:Health News:Moving closer to outdoor recreation not a recipe for being more physically active 2Health News:ESC announces new initiatives for workplace heart health programs 2Health News:ESC announces new initiatives for workplace heart health programs 3Health News:Cancer-associated long noncoding RNA regulates pre-mRNA splicing 2Health News:Cancer-associated long noncoding RNA regulates pre-mRNA splicing 3Health News:Surgery to Widen Neck Arteries Cuts 10-Year Stroke Risk: Study 2Health News:Surgery to Widen Neck Arteries Cuts 10-Year Stroke Risk: Study 3Health News:Black motorcyclists -- even in helmets -- more likely to die in crashes 2Health News:UCLA cancer researchers discover new signaling pathway that controls cell development and cancer 2Health News:UCLA cancer researchers discover new signaling pathway that controls cell development and cancer 3
... ,Allied Healthcares Timeter® PCS 414 portable air ... compressors that you may wonder if its running. ... features a durable, mar-resistant steel case thats easy ... only 26.5 pounds. The PCS 414 has been ...
... most compact, portable DC powered compressor ... provides the freedom to take nebulizer ... is powered by the included AC ... and Battery Kit. The integral reusable ...
The 45 PSI SuperSportNeb provides superior performance that translates to shorter treatment times. Like the SportNeb, it is constructed with die-cast aluminum compressor components for consistent rel...
... The new DeVilbiss PulmoAide Compact Compressor provides ... small size allows for therapy at home or ... a 5-year warranty, and the same reliable operation ... ,The PulmoAide Compact Compressor is the perfect ...
Medicine Products: